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P
harmacogenetics research looks at variations in the human genome and ways in which genetic factors might influence 
how individuals respond to drugs. The authors review basic principles of pharmacogenetics and cite findings from several 
gene-phenotype studies to illustrate possible associations between genetic variants, drug-related behaviors, and risk for drug 
dependence. Some gene variants affect responses to one drug; others, to various drugs. Pharmacogenetics can inform medica-
tion development and personalized treatment strategies; challenges lie along the pathway to its general use in clinical practice.
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S
ubstance dependence is a complex psychiatric disorder that develops in 
response to a combination of environmental and genetic risk factors and 
drug-induced effects (Ho et al., 2010). The strong genetic basis of depen-
dence is supported by family, adoption, and twin studies, which demonstrate 
substantial heritability, estimated to be about 50 percent (Uhl et al., 2008). The 
evidence suggests that no single variant accounts for a major portion of this risk, 
but that variations in many genes each contribute a small amount. 
Pharmacogenetics is the study of the genetic factors that influence drug response 
and toxicity. In this review, we briefly state the basic principles of pharmacoge-
netics and then provide examples of discoveries that demonstrate the impact of 
genetic variation on drug dependence, drug effects, and drug-induced behaviors. 
The primary goal of pharmacogenetic research into substance abuse is to better 
understand the sources of variation in the risk for dependence and the mechanisms 
involved. Some of the studies we discuss have identified genotypes that confer high 
risk for drug dependence, information that may be used to develop targeted, effec-
tive prevention programs. We also highlight how pharmacogenetics can advance 
the development of personalized treatments by revealing genetic variations that 
predict individual responses to therapeutic interventions.
principleS of pHarmacoGeneticS
Pharmacogenetics focuses on variation within the human genome. The human 
genome consists of some 30,000 genes, each composed of a sequence of hundreds 
to thousands of nucleotides (units of deoxyribonucleic acid, or DNA) (see Figure 
1). Every person inherits two copies of most genes, one from each parent. Although 
any two individuals’ DNA is over 99 percent identical, the number of  nucleotides 
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is so large—approximately 3 billion—that millions of 
variant sequences still occur across the human popula-
tion (Kruglyak and Nickerson, 2001). Variants that are 
found in more than 1 percent of the population are called 
polymorphisms. The most abundant type of variant is 
the single nucleotide polymorphism (SNP, pronounced 
“snip”); other common types are deletions, insertions, 
and tandem repeats (see Figure 2).
Each gene’s nucleotide sequence encodes (provides 
a template for) a molecular product, usually a protein. 
Sequence variation may result in alterations in the gene’s 
product, which in turn may have an effect on phenotypes 
(traits or characteristics, such as a disease or response to 
a drug) that the product influences. 
Genetic researchers use several types of studies to 
establish and explore gene-phenotype relationships. 
Heritability studies can indicate the relative contributions 
of genetic and nongenetic (e.g., environmental) influ-
ences to a particular phenotype. Linkage studies analyze 
pedigrees of related individuals and genetic markers 
to hone in on regions in the genome that may harbor 
genes associated with phenotypes of interest. Candidate 
gene association studies can be used to investigate gene-
phenotype relationships suggested by linkage studies, as 
well as to focus on genes selected for their physiological 
or pharmacologic relevance to a phenotype. Genome-
wide association (GWA) studies look for gene-phenotype 
relationships by simultaneously comparing hundreds of 
thousands of gene variants in DNA samples taken from 
large numbers of individuals.
Traditionally, pharmacogenetics has focused on the 
role of genetic variation in pharmacokinetics (e.g., the 
absorption, distribution, metabolism, and excretion of 
drugs) and pharmacodynamics (e.g., drug-response pro-
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one drug or to 
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Genes are distributed along chromosomes, which are long sequences of Dna. this illustration shows human chromosome 15 and highlights a hypo-
thetical gene at position 25 on the long (q) arm.
a gene is a sequence of Dna units, or nucleotides (adenine [a], cytosine [c], guanine [G], and thymine [t]). for a gene that determines a protein, the 
order of nucleotides precisely dictates the structure of an rna intermediate and a subsequent protein product. in contrast to this simplified illustra-
tion, actual genes are hundreds to thousands of nucleotides long, untranslated regions (Utrs) are hundreds of nucleotides long, and promoters are 
typically at least 40 nucleotides long.
each gene and its related Dna can be divided into segments:
promoter region: the genetic machinery anchors here to begin building the rna intermediate; sequence variation in this region may alter the 
machinery’s access to the gene and thereby affect its rate of rna and protein production.
exons: the genetic machinery transcribes these segments into an rna intermediate, then translates the rna intermediate (except for the rna that 
came from the Utrs) into the sequence of amino acids that constitutes the protein product; sequence variation within exons can alter that product 
(see figure 2).
introns: the genetic machinery transcribes these segments into rna but deletes them before translation into amino acids.  
Utrs: these regions serve regulatory functions and contribute to the stability of the rna intermediate; however, they are not translated into protein.
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fiGUre 2. Gene polymorphisms
polymorphism, or genetic variation in a gene’s Dna sequence, may result in alterations in the expression, regulation, and/or function of its protein 
product. the panels show five possible variants (alleles) of a hypothetical gene.
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Single Nucleotide Polymorphism (SNP)
Substitution of one DNA unit (a nucleotide) for another at a particular site (here, a C replaces an A found in wild-type triplet 1); the changed sequence of 
the triplet results in an altered amino acid in the protein product.
“Wild Type” Allele
The most common variant; note that the sequence of each DNA triplet determines one amino acid of the protein product.
Tandem Repeats
Addition of multiple copies of a DNA triplet (here, TAT), end-to-end; each new triplet can add one more copy of the amino acid it encodes to the 
protein product; the resulting elongated protein product may function differently than that produced by the gene’s wild-type variant.
Insertion
Intrusion of an additional DNA unit or units into the gene sequence (here, a C between the T and A in wild-type triplet 1); this may change 
not only the sequence of the triplet in which it occurs, but of all subsequent triplets, producing alterations in many amino acids of the protein 
product.
Deletion
Excision of a DNA unit or units (here, an A from wild-type triplet 1); this may change all subsequent triplets and the corresponding amino acids 
of the protein product.
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teins, such as receptors, channels, and transporters) (see 
Figure 3). However, candidate gene studies and, more 
recently, GWA studies have identified additional genetic 
influences on drug abuse and dependence. Because GWA 
studies cast a wide net and are without a hypothesis 
about which genes are involved, they are theoretically 
excellent tools for discovering novel common genetic 
variants and new genetic biomarkers that associate with 
particular phenotypes. For instance, GWA studies have 
shown that genes involved in cell adhesion, enzymatic 
activities, transcriptional regulation, and many other pro-
cesses and functions may be associated with dependence 
phenotypes (e.g., Ishiguro et al., 2008; Uhl et al., 2008).
The following sampling of pharmacogenetic find-
ings is not exhaustive but is intended to demonstrate 
the associations and predictive validity of some genetic 
variants conferring susceptibility for drug dependence 
or treatment response. (For further reading, see: Ho et 
al., 2010; Ho and Tyndale, 2007; Rutter, 2006; Uhl 
et al., 2008.)
pHarmacoGeneticS of SUBStance  
aBUSe vUlneraBility, acQUiSition,  
anD perSiStence
Some genetic variants alter the risk for dependence on 
one drug; others affect responses to various drugs. A 
variant that alters an enzyme that metabolizes a specific 
drug or a receptor activated by a specific drug is likely 
to play a role in vulnerability to dependence upon just 
that drug. In contrast, vulnerability to a variety of drugs 
could result from a variant that affects the brain reward 
pathways or neuroplasticity (the brain’s formation of 
new neural connections in response to experience or drug 
exposures) (Uhl et al., 2008). Genetic variation contrib-
uting to vulnerability to, and dependence on, different 
drug classes has been shown for the drug-metabolizing 
cytochrome P450 (CYP) enzymes, receptors such as 
the dopamine D2 receptor (DRD2) and mu opioid 
receptor (OPRM1), transporters such as the serotonin 
transporter (5-HTT) and dopamine transporter (DAT1), 
and enzymes such as dopamine β-hydroxylase (DβH) 
and monoamine oxidase (MAO).
cyps and Smoking
Variation in CYP2A6, the gene for the nicotine-metab-
olizing enzyme CYP2A6, influences aspects of smok-
ing dependence by altering nicotine pharmacokinet-
ics. CYP2A6 is primarily responsible for converting 
nicotine to cotinine, rendering it inactive (Benowitz 
and Jacob, 1994; Messina et al., 1997), and the enzyme 
further metabolizes cotinine to trans-3'-hydroxycoti-
nine (Nakajima et al., 1996). Individuals with different 
CYP2A6 variants can be grouped according to the result-
ing CYP2A6 enzyme activity as normal, intermediate 
(approximately 75 percent of normal), or slow (less 
than 50 percent of normal) metabolizers (Schoedel et 
al., 2004).
The CYP2A6  genotype (the pair of specific vari-
ants, or alleles, in a gene that a person inherits, one 
from each parent) has been associated with the risk for 
being a smoker and with numerous smoking behaviors. 
For instance, studies in novice adolescent smokers have 
found that slow and normal metabolizers differ in their 
risk for conversion to dependence, as defined in the 
International Classification of Diseases, 10th Revision 
(ICD-10) (O’Loughlin et al., 2004) and in the rate at 
which they progress to increasingly severe dependence 
(Audrain-McGovern et al., 2007). Among adult smokers, 
slow metabolizers are less prevalent than intermediate 
or normal metabolizers; they smoke fewer cigarettes per 
day, exhibit reduced cigarette puffing, have decreased 
dependence, wait longer to smoke the first cigarette of 
the day, and have fewer nicotine withdrawal symptoms; 
and they make up a smaller portion of smokers as the 
duration of smoking increases, suggesting that they quit 
smoking sooner (Kubota et al., 2006; Malaiyandi et al., 
2006; Schoedel et al., 2004; Strasser et al., 2007). 
These findings suggest that nicotine levels remain 
elevated longer in smokers with slow-metabolizing 
CYP2A6 variants than those with fast-metabolizing 
variants, resulting in a decreased need to light up or 
puff as often to avoid withdrawal. This reduced fre-
quency of exposure to nicotine over time may decrease 
nicotine-induced changes in the brain, resulting in less 
severe dependence and perhaps more successful quitting 
attempts. Although not all studies agree on these asso-
ciations, variation in CYP2A6’s metabolic inactivation 
of nicotine appears, on balance, to be associated with 
variation in smoking behavior and may alter cessation 
rates (Munafo et al., 2004).
cyps and opioid Dependence 
Several oral opioids, such as codeine, oxycodone, and 
hydrocodone, are metabolized by another CYP enzyme, 
CYP2D6, to more psychoactive metabolites, such as mor-
phine, oxymorphone, and hydromorphone (Otton et al., 
1993). The CYP2D6 gene is highly polymorphic, with 
some variants leading to a completely inactive enzyme. 
a dopamine 
transporter 
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Individuals who inherit such defective CYP2D6 alleles 
from both parents are referred to as poor metabolizers 
(Alvan et al., 1990). Poor CYP2D6 metabolizers are 
underrepresented among people dependent on oral opi-
oids, suggesting that the CYP2D6 defective genotype is 
a pharmacogenetic protection factor against oral opioid 
dependence (Tyndale et al., 1997). Of note, CYP2D6 
variation should not play a role in dependence on intra-
venously administered opioids (e.g., morphine) as these 
drugs are already psychoactive and do not depend on 
CYP2D6 activity for metabolic activation. 
Dopamine receptors
Drugs of abuse activate the mesolimbic dopaminergic 
pathway, which plays an essential role in drug reward 
and reinforcement (Di Chiara and Bassareo, 2007). A 
key mechanism in this pathway is dopamine activation 
of DRD2 receptors on dopaminergic neurons in the 
ventral tegmental area (Cohen et al., 2007; Di Chiara 
and Imperato, 1988; Koob, 2006). Accordingly, stud-
ies have examined the impact of genetic variation in 
DRD2 on responses to several drugs of abuse, and several 
polymorphisms have been implicated in susceptibility 
and dependence.
For instance, one DRD2 variant, called TaqI A, results 
from a SNP (32806C>T) that occurs in the DRD2-
neighboring ankyrin repeat and kinase domain containing 
1(ANKK1) gene. Although this variant does not lie within 
the DNA region that encodes the DRD2 protein, it is 
nonetheless associated with a lower density of DRD2 
receptors and consequently decreased dopaminergic 
activity (Noble et al., 1993). TheTaqI A  polymorphism 
may contribute to vulnerability to substance abuse and 
has been associated with polysubstance abuse (O’Hara 
fiGUre 3. Generic neurotransmitter System
Gwa studies 
have made 
nicotinic  
acetylcholine  
subunit genes 
a focus of 
pharmacoge-
netic research 
on smoking.
neurotransmitters, such as dopamine and acetylcholine, are chemicals that carry signals from neuron to neuron across  
gaps called synapses. a sending neuron synthesizes neurotransmitter molecules and bundles them into packages; when the 
neuron becomes electrically excited, it releases the neurotransmitter molecules into the synapse. once in the synapse, each 
molecule may:
• dock on a receptor on the receiving neuron, initiating a cellular response; 
• re-enter the sending neuron via a molecular conduit called the transporter;
• encounter a metabolizing or degrading enzyme that destroys it.
Drugs of abuse produce psychoactive effects by disrupting the normal balance of neurotransmitter release, signaling, recovery, 
and metabolism. Genetic variation in receptors, transporters, or enzymes can limit or exacerbate these effects and thereby 
affect susceptibility to drug abuse and dependence.
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et al.,1993), heroin use (Lawford et al., 2000), cocaine 
dependence (Noble et al., 1993), and psychostimulant 
polysubstance abuse (Persico et al., 1996). Some studies 
have suggested that TaqI A is a risk factor for smoking 
behaviors (Comings et al., 1996; Erblich et al., 2005; 
Huang et al., 2009), while other studies have not found 
these associations (Berlin et al., 2005; Johnstone et al., 
2004; Singleton et al., 1998).
Another variant associated with the DRD2 gene, 
called TaqI B, located in exon 2, also results in lower 
density of DRD2 receptors in the striatum. Individu-
als with this variant are more likely than those without 
it to have smoked and to have started smoking at an 
earlier age (Spitz et al., 1998; Wu et al., 2000) to be 
cocaine-dependent (Noble et al., 1993), and to abuse 
psychostimulants (Persico et al., 1996). Additionally, 
a deletion variant (-141C Del) in the promoter region 
was associated with higher density of DRD2 receptors 
in the striatum (Jonsson et al., 1999) and with a higher 
likelihood of heroin abuse by inhalation, but not by injec-
tion (Li et al., 2002). These data suggest that, consistent 
with the key role of the dopamine receptor in the reward 
pathway, variation in DRD2 may alter multiple aspects 
of dependence for many drugs of abuse. 
other Dopamine pathway components
Genetic variation in other components of the dopamine 
transmission system has also been implicated in substance 
abuse. For instance, the gene SLC6A3 encodes the dopa-
mine transporter (DAT1), which regulates dopamine 
activity by drawing the neurotransmitter back into pre-
synaptic neurons and terminating its action. Cocaine 
inhibits the dopamine transporter, which contributes 
to the drug’s reinforcing effects.
Genetic variants consisting of variable numbers of 
tandem repeats (VNTR) of a 40-nucleotide unit can 
occur in exon 15 of SLC6A3 (Vandenbergh et al., 1992). 
Studies have associated these variants with cocaine-
induced paranoia but not cocaine dependence (Gelernter 
et al., 1994) and with methamphetamine-induced psy-
chosis (Ujike et al., 2003) but not with methamphet-
amine abuse or subjective responses to acute metham-
phetamine (Hong et al., 2003; Lott et al., 2005). These 
findings suggest a distinct role for this SLC6A3 genetic 
variation in drug-induced paranoia and psychosis, which 
appears to be unrelated to drug abuse and dependence. 
However, a different VNTR variant of SLC6A3—con-
sisting of repeats of a unit of 30 nucleotides in intron 
8—has been associated with cocaine abuse in a Brazilian 
population (Guindalini et al., 2006).
Variation in genes for dopamine-metabolizing 
enzymes has also been implicated in drug effects. The 
DβH gene encodes dopamine beta hydroxylase (DβH), 
an enzyme that metabolizes dopamine to norepinephrine 
(Stewart and Klinman, 1988). Two polymorphisms in 
DβH—an insertion-deletion variant (DβH5'-Ins/Del) 
and a SNP (444G>A)—are often inherited together 
and have been associated with cocaine-induced para-
noia (Yamamoto et al., 2003). The enzyme MAO-A 
metabolizes a broad array of drugs and other molecules, 
including the neurotransmitters serotonin, dopamine, 
and norepinephrine (Shih et al., 1993). A VNTR poly-
morphism in the promoter region of the MAO-A gene 
has been associated with risk for substance use disorders 
(Vanyukov et al., 2004; Vanyukov et al., 2007). A variant 
with three repeats of a 30-nucelotide segment results in 
decreased expression of the MAO-A gene compared with 
variants having 3.5 or 4 repeats (Deckert et al., 1999; 
Denney et al., 1999; Sabol et al., 1998). Some studies 
have associated the low-activity variant with increased 
susceptibility to alcoholism (Contini et al., 2006; Huang 
et al., 2007; Saito et al., 2002) and antisocial alcohol-
ism (Samochowiec et al., 1999; Schmidt et al., 2000), 
although other studies have found no such associations 
(Lu et al., 2002; Mokrovic et al., 2008).
the opioid System
Genetic variation in the opioid system has been impli-
cated in altered risk for drug dependence. For instance, 
the OPRM1 gene encodes the receptor for beta-endor-
phin (an opioid produced naturally by the body) as well 
as for opiate and opioid drugs and the psychoactive 
metabolites of heroin (morphine and 6-monoacetylmor-
phine) (Ho et al., 2010). The most common OPRM1 
SNP (A118G) occurs in exon 1 and alters an amino acid 
(Asn40Asp) in the receptor (Bond et al., 1998; Zhang 
et al., 2005). 
Studies of the effect of this variant on receptor func-
tion have yielded contradictory results. Some suggest 
that receptors encoded by this OPRM1 variant have an 
increased affinity for beta-endorphin and greater receptor 
activation upon binding (Bond. et al., 1998), while others 
have found no change in receptor function, signaling, or 
binding affinities for various opioids (Befort et al., 2001; 
Beyer et al., 2004). Although variation in OPRM1 has 
been found to contribute to the risk for heroin addic-
tion in some populations (Bart et al., 2004; Szeto et al.,
2001), not all studies agree (Bond et al., 1998; Tan et 
an opioid 
receptor 
gene variant 
may predict 
responses to 
naltrexone 
therapy for 
alcoholism.r e S e a r c H   r e v i e w — p H a r m a c o G e n e t i c S   •   2 3
al., 2003). The A118G variant was also associated with 
increased risk of developing alcoholism (Bart et al., 2005).
the Serotonin transporter
The serotonin transporter (5-HTT) is encoded by the 
SLC6A4 gene and directs the reuptake of serotonin 
from the synapse into the presynaptic neuron. This 
gene’s promoter region (5-HTTLPR) occurs in short and 
long variants, depending on whether a 44-nucleotide 
sequence is deleted or not. The short variant reduces the 
transcriptional efficiency of the gene promoter, lead-
ing to decreased production of 5-HTT and hence a 
dysfunctional serotonin reuptake mechanism (Heils et 
al., 1996; Lesch et al., 1996). 
The genotype in which both copies of the gene are 
short (s/s) has been associated with heroin dependence, 
particularly in violent heroin-dependent users, among 
Caucasian Italians. This finding is consistent with a 
hypothesis linking the 5-HTTLPR s/s genotype to a gen-
eral behavioral disorder characterized by aggressiveness, 
impulsiveness, and vulnerability to addiction (Gerra et 
al., 2004). However, a study in Chinese subjects did not 
find an association between 5-HTTLPR variation and 
heroin dependence (Li et al., 2002).
Studies have suggested a possible role for serotonin 
transmission in susceptibility to nicotine dependence 
with the 5-HTTLPR s/s genotype being associated with 
personality traits (e.g., neuroticism) typical of smoking 
behavior (Hu et al., 2000; 1996; Lerman et al., 2000; 
Lesch et al., 1996). However, not all studies agree. In 
adolescents, the s/s genotype frequency was significantly 
higher among smokers compared with nonsmokers, 
and among heavy smokers who started smoking early 
compared with moderate smokers who started smok-
ing later (Gerra et al., 2005). Other studies found that 
individuals with the s/s genotype were less inclined to 
smoke (Ishikawa et al., 1999) or found no association 
between 5-HTTLPR and smoking (Lerman et al., 1998; 
Sieminska et al., 2008; Trummer et al., 2006).
Genome-wide association Studies
Whole-genome association techniques have provided 
some novel insights into genetic influences on drug 
dependence (Liu et al., 2006). For instance, GWA stud-
ies have revealed previously unrecognized influences on 
the development of nicotine dependence (Bierut et al., 
2007). As a result of those studies, variation in nicotinic 
receptor genes has become a focus of pharmacogenetic 
research (see Figure 4).
This research has drawn attention to region 15q25 
(region 25 of the long arm of chromosome 15), which 
includes a cluster of genes that encode subunits of the 
nicotinic acetylcholine receptor: CHRNA3 (encodes 
the α3 subunit), CHRNA5 (encodes the α5 subunit), 
and CHRNB4 (encodes the β4 subunit). Some GWA 
studies have found a direct association between 15q25 
variation and lung cancer risk that may be independent 
of smoking behavior or nicotine addiction (Amos et 
al., 2008; Hung et al., 2008), while others have associ-
ated 15q25 variation with smoking quantity, nicotine 
dependence, and lung cancer risk (Thorgeirsson et al., 
2008). This gene cluster has also been associated with 
risk for chronic obstructive pulmonary disease (Pillai 
et al., 2009). 
The GWA findings are in accord with candidate 
gene studies that have linked variation in CHRNA3 and 
CHRNA5 with the number of cigarettes smoked per 
day (Berrettini et al., 2008) and increased absorption 
of nicotine and tobacco toxins (e.g., nitrosamines) per 
cigarette (Le Marchand et al., 2008). Candidate gene 
studies have also associated variation in CHRNA5 with 
risk of developing nicotine dependence once a person 
begins to smoke cigarettes (Saccone et al., 2007) and 
with experiencing a pleasurable rush or buzz during the 
initial phases of smoking (Sherva et al., 2008). These 
findings suggest that variation in nicotinic receptor sub-
unit genes may be implicated in smoking behaviors, 
nicotine dependence, and subsequent tobacco-related 
illnesses, such as lung cancer and chronic obstructive 
pulmonary disease. 
The cost-effectiveness of GWA studies has been 
questioned because some of the gene-phenotype relation-
ships they reveal do not appear to be very strong, while 
others would be logical targets for exploration using less 
expensive candidate gene studies. For example, nicotinic 
acetylcholine receptors are the primary drug targets for 
nicotine in the brain, and thus their biological relevance 
makes them promising subjects for candidate gene studies 
independent of the GWA results. 
However, other GWA studies have identified genetic 
variants that were not obvious targets for candidate gene 
studies and may contribute to addiction vulnerability 
through previously unsuspected mechanisms, includ-
ing cell adhesion; protein translation, trafficking, and 
degradation; transcriptional regulation; transport pro-
cesses; and cell structures. Once discovered by GWA, 
these genes become high-priority subjects for candidate 
studies and biochemical pathway analyses. 
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pHarmacoGeneticS of SUBStance aBUSe 
treatment 
The enormous personal and societal costs of substance use 
and abuse (Rehm et al., 2006) dictate a need for effective 
interventions. Two strategies for achieving improved 
treatment outcomes are to optimize pharmacotherapies 
and to personalize treatment options (Rutter, 2006). 
Here we review a selection of studies that have linked 
genetic variation to treatment response and hence may 
advance progress toward these two goals. 
As mentioned above, CYP2A6 genetic variation has 
been associated with smoking dependence and behavior, 
suggesting that it might also affect response to nicotine 
replacement therapy. Researchers investigated this 
hypothesis in a study with Caucasian smokers who were 
given standard, 8-week courses of the nicotine patch or 
spray (Malaiyandi et al., 2006). The results confirmed 
that CYP2A6 genotype influences smoking behavior, 
but the impact on quitting could not be determined due 
to the small sample size. However, slow CYP2A6 activ-
ity, as measured by blood levels of nicotine metabolites, 
was associated with higher plasma nicotine levels and 
substantially greater quitting success with the nico-
tine patch in multiple studies (Lerman et al., 2006a; 
Schnoll et al., 2009). In contrast, slow metabolizers 
had equal quit rates relative to normal metabolizers in 
the group that used the nicotine spray. Nicotine spray, 
like cigarette smoking, allows titration for differences 
in nicotine need and rates of metabolism. Recently we 
have also shown, using either the CYP2A6 genotype or 
the nicotine metabolite phenotype measure, that slow 
metabolizers respond better to extending the duration 
of nicotine patch treatment (Lerman et al., 2010).
 In a study comparing placebo with bupropion 
(Zyban), slow CYP2A6 metabolizers achieved supe-
rior quit rates during treatment with placebo compared 
with fast metabolizers (Patterson et al., 2008). This 
finding is consistent with a role for CYP2A6 in smok-
ing behaviors—such as amount smoked and smoking 
duration—that can alter smoking cessation outcomes. In 
addition, when bupropion was compared with placebo, 
only fast CYP2A6 metabolizers received any additional 
fiGUre 4. nicotinic acetylcholine receptor
nicotine initiates its effects by activating nicotinic acetylcholine receptors (nachrs). the normal function of these receptors is 
to respond to the neurotransmitter acetylcholine, but the nicotine molecule binds to the same sites that acetylcholine does and 
also stimulates the receptors.
when nicotine attaches to an nachr, its impact depends on the combination of subunits making up the receptor. each nachr 
consists of five subunits, drawn from a set of twelve types, designated alpha 2 to 10 and beta 2 to 4. Some types are more 
responsive to nicotine than others. Genetic variation in the subunits also can affect their sensitivity to nicotine and thereby 
alter vulnerability to smoking and many aspects of the smoking experience and behavior.
α4
β2 β2
α4
β2
α6
β2 β2
α6
Binding sites
Nicotinic acetylcholine receptors
β3
Nicotine
Synaptic
space
Cell membrane
Cell interior
Acetylcholine
J
i
m
 
P
e
r
k
i
n
sr e S e a r c H   r e v i e w — p H a r m a c o G e n e t i c S   •   2 5
benefit (Patterson et al., 2008). Together, these data sug-
gest that CYP2A6 slow metabolizers have superior quit 
rates even in the absence of active drug, and this effect 
is enhanced by the nicotine patch. In contrast, CYP2A6 
fast metabolizers do poorly in the absence of pharma-
cotherapy and respond relatively well to bupropion.
The cytochrome P450 enzyme CYP2B6 is respon-
sible for metabolizing bupropion to hydroxybupropion 
(Faucette et al., 2000). The CYP2B6 gene sequence is 
variable, and some variants result in altered CYP2B6 
activity (Hesse et al., 2004; Kirchheiner et al., 2003). For 
example, the CYP2B6*6 variant (G516T and A785G), 
which is found in 45 percent of Caucasians, 50 percent 
of African-Americans, and 25 percent of Asians, results 
in decreased bupropion metabolism (Hesse et al., 2004). 
In a clinical trial of bupropion versus placebo (Lee et 
al., 2007), smokers with one or two CYP2B6*6 alleles 
achieved significantly higher abstinence rates with bupro-
pion than with placebo. In contrast, smokers with two 
copies of the more common CYP2B6*1 allele showed no 
difference in abstinence between bupropion and placebo 
treatment. This study, if replicated, would suggest that 
smokers with the CYP2B6*6 variant should be treated 
with bupropion, but smokers with the CYP2B6*1/*1 
genotype are unlikely to benefit from this medication 
(Lee et al., 2007).
Variation in the genes that encode nicotinic receptors 
also alters smoking behaviors and smoking cessation rates. 
In one study, a SNP (rs2072661) in the 3' untranslated 
region of the CHRNB2 gene, which encodes the β2 sub-
unit of the nicotinic receptor, affected abstinence rates at 
the end of smoking cessation treatment; individuals with 
the less common allele also had substantially decreased 
odds of being abstinent at the 6-month followup (Conti 
et al., 2008). Furthermore, this SNP was associated 
with reduced withdrawal symptoms at the target quit 
date and increased the time to relapse. Overall, while 
these results provide strong evidence for CHRNB2 in 
the ability to quit smoking, they require replication in 
an independent sample.
The dopaminergic system has also been implicated 
in the response to therapeutic interventions for drug 
dependence. For instance, just as the TaqI A variant of 
the DRD2 gene has been associated with heroin depen-
dence, it has also been associated with poor methadone 
treatment outcomes (Lawford et al., 2000). Additionally, 
smokers with the InsC genotype of the DRD2  promoter 
region polymorphism at -141C responded more favor-
ably to smoking cessation treatment with bupropion, 
but less favorably to nicotine replacement therapy with 
the patch or spray (Lerman et al., 2006b). Furthermore, 
smokers with two copies of a DRD2 SNP (957C>T) 
responded better to nicotine replacement therapy than 
smokers with one or no copies of the variant.
Beta-endorphin is released upon acute and short-term 
nicotine administration and exhibits rewarding effects. 
The common OPRM1 A118G variant was thought to 
alter the receptor’s binding affinity for beta-endorphin, 
but it may play a larger role in altering messenger RNA 
(mRNA; see Figure 1) and OPRM1 receptor levels 
(Bond et al., 1998; Zhang et al., 2005). Smokers with 
this variant were more likely to be abstinent at the end 
of 8 weeks of nicotine replacement therapy, with more 
pronounced effects in those receiving the patch versus 
the spray, compared with smokers homozygous for the 
most common OPRM1 allele (Lerman et al., 2004). 
The OPRM1 A118G variant may also predict nal-
trexone response for the treatment of alcoholism. In 
placebo-controlled clinical trials, individuals with this 
SNP were more responsive to naltrexone treatment 
(Anton et al., 2008; Oroszi et al., 2009), took a longer 
time to relapse to drinking, and relapsed at lower rates 
(Oslin et al., 2003; Kim, et al., 2009) compared with 
individuals without the variant. However, the association 
between OPRM1 A118G and response to treatment was 
not replicated in other clinical trials with naltrexone (Gel-
ernter et al., 2007; Mitchell et al., 2007) or nalmefene 
(Arias et al., 2008).
The progression from pharmacogenetic discovery 
to better substance abuse treatment may be shortened 
if researchers develop and use phenotype measures 
(e.g., amount smoked, ability to stop for a short time, 
motivation to stop, treatment seeking) that are infor-
mative both for pharmacogenetic studies and in the 
screening of human medication development (Perkins 
et al., 2008). Such an effort should also address the 
need for uniform phenotype measures that will facili-
tate comparison and replication of pharmacogenetic 
findings. Researchers’ use of broad or inconsistent 
phenotype definitions is a major reason why con-
tradictory conclusions about genetic effects on phe-
notypes—such as many noted above—are common   
in the pharmacogenetic literature (Szatmari et al., 
2007).
pHarmacoGeneticS in tHe clinic
The Food and Drug Administration (FDA) recognizes 
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and patient care, provides information for understand-
ing the role of such discoveries in regulatory judgments, 
and has approved the inclusion of pharmacogenetic test 
information in the labeling of selected drugs (Food and 
Drug Administration, 2008; Frueh et al., 2008; Shin 
et al., 2009). However, challenges will need to be met 
before the full potential of pharmacogenetic discoveries 
to advance clinical practice can be realized.
Demonstrating the clinical validity and utility of 
pharmacogenetic testing is among the greatest hurdles 
facing the widespread application of pharmacogenetics 
in clinical practice. To be accepted, the use of pharma-
cogenetic testing to guide treatment must demonstra-
bly improve clinical outcomes (Hunter et al., 2008). 
However, as this article has highlighted, attempts to 
replicate studies that have shown benefit to such testing 
have often failed. The question arises: What degree of 
clinical benefit is sufficiently robust to warrant clinical 
implementation?
Once the clinical benefits and risks of pharmacoge-
netic optimization of a treatment are clearly defined, the 
question of cost-effectiveness may still remain (Heitjan 
et al., 2008). Complicated ethical and privacy issues 
raised by the use of pharmacogenetic tests are the focus 
of other reviews (Marx-Stolting, 2007; Shields and Ler-
man, 2008; van Delden et al., 2004).
If pharmacogenetic testing is to become widely 
accepted as a clinical diagnostic tool, who should be 
carrying out the tests? Currently, testing is done by using 
FDA-approved in vitro diagnostic devices and kits sold 
by manufacturers or, more commonly, by clinical labo-
ratories that are not FDA-approved (Shin et al., 2009). 
With such a variety of testing options, strict monitoring 
systems are needed to guarantee reliable results (Hunter 
et al., 2008).
The limited availability and cost of pharmacogenetic 
testing are additional challenges (Tucker, 2008). Most 
insurance plans will reimburse the cost of pharmacoge-
netic testing only if it is required by the FDA, medically 
necessary, or has proven clinical utility (Shin et al., 2009).
Studies have shown that pharmacogenetic variation 
can significantly alter susceptibility to, and response to 
treatment for, drug dependence. It is important that 
we evaluate current approaches and address concerns 
appropriately in order to optimize the management of 
drug dependence through the use of pharmacogenetics.
conclUSionS
We have highlighted several pharmacogenetic find-
ings that contribute to the understanding of substance 
dependence and to the variation in responses to substance 
abuse treatment. Clearly, environmental factors also play 
a role, and future studies of pharmacogenetics will be 
improved if they are large enough to investigate both 
gene-gene and gene-environment interactions. We hope 
that a better understanding of the role of genetic factors 
will contribute to the optimal use of current therapies 
and the development of novel and potentially more 
effective therapeutic strategies. 
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